Mushroom Toxicity Mechanisms and Clinical Management

Fungi in several genera, most notably Amanita, Galerina and Lepiota, produce potent cyclic peptide toxins (amatoxins and phallotoxins) and other alkaloids that cause high‐morbidity poisonings worldwide. Amatoxins, such as α-amanitin, bind to and inhibit RNA polymerase II, triggering hepatocellular apoptosis and necrosis after a symptom-free latency. Phallotoxins disrupt actin polymerisation, intensifying tissue injury, while muscarine and other compounds affect autonomic receptors or induce oxidative stress. Clinical presentation typically progresses from gastrointestinal distress to hepatic and renal dysfunction. Management hinges on prompt decontamination, activated charcoal, aggressive fluid and electrolyte resuscitation, correction of coagulopathy and metabolic disturbances, and consideration of specific antidotes (for example silibinin or N-acetylcysteine). Extracorporeal liver support systems and orthotopic liver transplantation remain definitive treatments for fulminant liver failure. Recent advances emphasise targeted pharmacological inhibitors, refined extracorporeal elimination techniques and rapid diagnostics to improve triage and outcomes. The global burden of mushroom intoxication underscores the need for integrated surveillance, public education and accessible therapies in both high- and low-resource settings.

Research from Nature Portfolio

Recent studies have employed genome‐wide CRISPR screening and in silico drug repurposing to dissect α-amanitin toxicity and identify candidate antidotes. One investigation revealed that the oligosaccharyltransferase subunit STT3B is critical for cellular uptake and cytotoxicity of α-amanitin. By screening existing clinical dyes, researchers found that indocyanine green inhibits STT3B, effectively blocking toxin internalisation and preventing liver damage in organoid and murine models. This integrated approach demonstrates the power of functional genomics to accelerate the discovery of mechanism-based therapeutics for lethal mushroom poisoning.

Mushroom Toxicity Mechanisms and Clinical Management publication trend

The graph below shows the total number of articles in mushroom toxicity mechanisms and clinical management across all publications each year (not limited to Nature Index journals).

Technical terms

α-amanitin: A cyclic octapeptide toxin that potently inhibits RNA polymerase II, causing hepatocellular failure.

STT3B: Catalytic subunit of the oligosaccharyltransferase complex involved in N-glycan biosynthesis, identified as essential for α-amanitin toxicity.

N-glycan biosynthesis: A post-translational modification pathway for glycoprotein folding and stability, implicated in toxin internalisation.

MSDIN gene family: A cluster of ribosomally encoded genes in Amanita species that produce precursor peptides for amatoxins and phallotoxins, diversified by natural selection.

Lateral flow immunoassay (LFIA): A rapid, antibody-based diagnostic strip test that visually detects small molecules in fluids without complex instrumentation.

References

1. Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity. Nature Communications (2023).
2. Pangenomics of the death cap mushroom Amanita phalloides, and of Agaricales, reveals dynamic evolution of toxin genes in an invasive range. The ISME Journal: Multidisciplinary Journal of Microbial Ecology (2023).
3. Lateral flow immunoassay (LFIA) for the detection of lethal amatoxins from mushrooms. PLOS ONE (2020).